Fluoxetine

Summary

Fluoxetine (CHEMBL41) is an approved small molecule (ATC N06AB03) targeting SLC29A4, HTR6, and KCNJ6; indicated across 38 conditions including stroke disorder and fibromyalgia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AB03
• Targets: 9 (SLC29A4, HTR6, KCNJ6…)
• Indications: 38 conditions
• Clinical trials: 204
• Chemistry: 309.33 Da · C17H18F3NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL41
Name	Fluoxetine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3386
ChEBI	CHEBI:86990
ATC	N06AB03
Molecular formula	C17H18F3NO
Molecular weight	309.33
InChIKey	RTHCYVBBDHJXIQ-UHFFFAOYSA-N

SMILES: CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F

IUPAC name: N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine

ChEBI definition: An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Also known as: Fluoxetin ratiopharm, Fluoxetina, Fluoxetine, Fluval, NSC-283480, NSC-758685, Symbyax, fluoxetine, Fluxetine, (+/-)-Fluoxetine, SID26751973, SID26755310

Parent form; salt/anhydrous children: CHEMBL1201082

Patent coverage: 17,245 distinct patent families (62,368 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SLC29A4	Plasma membrane monoamine transporter	Inhibition	4.64	0.7%	Q7RTT9
HTR6	5-HT6 receptor	Antagonist	5.8	0.2%	P50406
KCNJ6	Kir3.2	Antagonist	4.8	0.1%	P48051
KCNC1	Kv3.1		6.1	1.7%	P48547
HTR2A	5-HT2A receptor	Antagonist	6.5	0%	P28223
ANO1	CaCC	Inhibition		1.2%	Q5XXA6
HTR2B	5-HT2B receptor	Antagonist	5.3	0.4%	P41595
HTR2C	5-HT2C receptor	Antagonist	7.3	0%	P28335
SLC6A4	SERT	Inhibition	8.5	0.7%	P31645

Broader ChEMBL bioactivity targets: 51 (assay-derived). Sample: Prelamin-A/C, NPC intracellular cholesterol transporter 1, Ras-related protein Rab-9A, 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Adrenergic receptor alpha-1, Voltage-dependent L-type calcium channel subunit alpha-1C, Histamine H2 receptor, Alpha-2B adrenergic receptor, Muscarinic acetylcholine receptor M5.

Bioactivity

ChEMBL activities: 193 potent at pChembl ≥ 5 of 215 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC6A4	9.57	Ki	0.27	nM	CHEMBL_ACT_7667829
SLC6A4	9.29	IC50	0.51	nM	CHEMBL_ACT_7667828
SLC6A4	9.14	Ki	0.72	nM	CHEMBL_ACT_1608913
SLC6A4	9.09	Kd	0.81	nM	CHEMBL_ACT_146151
SLC6A4	8.96	Ki	1.1	nM	CHEMBL_ACT_2263570
SLC6A4	8.96	Ki	1.1	nM	CHEMBL_ACT_2607121
SLC6A4	8.85	Ki	1.4	nM	CHEMBL_ACT_13340278
SLC6A4	8.7	Ki	2	nM	CHEMBL_ACT_1953185
SLC6A4	8.66	Ki	2.2	nM	CHEMBL_ACT_1978198
SLC6A4	8.66	Ki	2.2	nM	CHEMBL_ACT_2015321
SLC6A4	8.66	Ki	2.2	nM	CHEMBL_ACT_2023010
SLC6A4	8.6	IC50	2.5	nM	CHEMBL_ACT_3106196
SLC6A4	8.57	EC50	2.7	nM	CHEMBL_ACT_10836341
P31652	8.57	Ki	2.7	nM	CHEMBL_ACT_2452759
P31652	8.57	Ki	2.7	nM	CHEMBL_ACT_2678801
P31652	8.56	Ki	2.72	nM	CHEMBL_ACT_1156877
P31652	8.55	Ki	2.8	nM	CHEMBL_ACT_1953184
P31652	8.54	Ki	2.9	nM	CHEMBL_ACT_1978188
P31652	8.54	Ki	2.9	nM	CHEMBL_ACT_2015290
P31652	8.54	Ki	2.9	nM	CHEMBL_ACT_2022986
SLC6A4	8.51	IC50	3.1	nM	CHEMBL_ACT_3414443
SLC6A4	8.5	Ki	3.17	nM	CHEMBL_ACT_192904
SLC6A4	8.46	Ki	3.5	nM	CHEMBL_ACT_447986
SLC6A4	8.45	IC50	3.58	nM	CHEMBL_ACT_17702487
SLC6A4	8.45	IC50	3.58	nM	CHEMBL_ACT_22850858
P31652	8.41	Ki	3.9	nM	CHEMBL_ACT_1736431
P31652	8.41	Ki	3.9	nM	CHEMBL_ACT_2470774
SLC6A4	8.4	IC50	4	nM	CHEMBL_ACT_20634537
SLC6A4	8.3	IC50	5.01	nM	CHEMBL_ACT_5238547
SLC6A4	8.3	IC50	5.01	nM	CHEMBL_ACT_6305167

Target pathways

Aggregated over 9 target gene(s): SLC29A4, HTR6, KCNJ6, KCNC1, HTR2A, ANO1, HTR2B, HTR2C, SLC6A4.

Top Reactome pathways

37 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	4	HTR2A, HTR2B, HTR2C, HTR6
Signaling by GPCR	4	HTR2A, HTR2B, HTR2C, HTR6
Class A/1 (Rhodopsin-like receptors)	4	HTR2A, HTR2B, HTR2C, HTR6
Amine ligand-binding receptors	4	HTR2A, HTR2B, HTR2C, HTR6
GPCR downstream signalling	4	HTR2A, HTR2B, HTR2C, HTR6
Serotonin receptors	4	HTR2A, HTR2B, HTR2C, HTR6
GPCR ligand binding	4	HTR2A, HTR2B, HTR2C, HTR6
Neuronal System	3	KCNC1, KCNJ6, SLC6A4
G alpha (q) signalling events	3	HTR2A, HTR2B, HTR2C
Transmission across Chemical Synapses	2	KCNJ6, SLC6A4
Potassium Channels	2	KCNC1, KCNJ6
Transport of small molecules	2	ANO1, SLC29A4
Neurotransmitter clearance	1	SLC6A4
Neurotransmitter receptors and postsynaptic signal transmission	1	KCNJ6
Activation of G protein gated Potassium channels	1	KCNJ6
G protein gated Potassium channels	1	KCNJ6
Inwardly rectifying K+ channels	1	KCNJ6
Voltage gated Potassium channels	1	KCNC1
Disease	1	ANO1
Stimuli-sensing channels	1	ANO1
Serotonin clearance from the synaptic cleft	1	SLC6A4
G alpha (s) signalling events	1	HTR6
Transport of vitamins, nucleosides, and related molecules	1	SLC29A4
SLC-mediated transmembrane transport	1	SLC29A4
SLC-mediated transport of neurotransmitters	1	SLC6A4
Infectious disease	1	ANO1
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane	1	SLC29A4
SARS-CoV Infections	1	ANO1
SARS-CoV-2 Infection	1	ANO1
Induction of Cell-Cell Fusion	1	ANO1

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	4
chemical synaptic transmission	4
signal transduction	4
G protein-coupled receptor signaling pathway	4
G protein-coupled serotonin receptor signaling pathway	4
monoatomic ion transport	3
monoatomic ion transmembrane transport	3
intracellular calcium ion homeostasis	3
phospholipase C-activating serotonin receptor signaling pathway	3
serotonin receptor signaling pathway	3
response to xenobiotic stimulus	3
positive regulation of phosphatidylinositol biosynthetic process	3
release of sequestered calcium ion into cytosol	3
positive regulation of ERK1 and ERK2 cascade	3
neurotransmitter transport	2

Indications & clinical

Indications

38 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
stroke disorder	3	MONDO:0005098	EFO:0000712
fibromyalgia	3	MONDO:0005546	EFO:0005687
autism	3	MONDO:0005260	EFO:0003758
obsessive-compulsive disorder	3	MONDO:0008114	EFO:0004242
post-traumatic stress disorder	3	MONDO:0005146	EFO:0001358
intracerebral hemorrhage	3	MONDO:0013792	EFO:0005669
nicotine dependence	3	MONDO:0008575	EFO:0003768
anxiety	3	MONDO:0011918	EFO:0005230
social phobia	3	MONDO:0001247	EFO:1001917
dementia	3	MONDO:0001627	HP:0000726
major depressive disorder	3	MONDO:0002009	MONDO:0002009
depressive disorder	3	MONDO:0002050	MONDO:0002050
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
enuresis	3	MONDO:0024290	MONDO:0024290
influenza	3	MONDO:0005812	EFO:0007328
bipolar disorder	3	MONDO:0004985	MONDO:0004985
anxiety disorder	3	MONDO:0005618	EFO:0006788
gastroesophageal reflux disease	2	MONDO:0007186	EFO:0003948
pulmonary arterial hypertension	2	MONDO:0015924	EFO:0001361
epilepsy	2	MONDO:0005027	EFO:0000474
multiple system atrophy	2	MONDO:0007803	EFO:1001050
obesity disorder	2	MONDO:0011122	EFO:0001073
cocaine dependence	2	MONDO:0005186	EFO:0002610
panic disorder	2	MONDO:0005383	EFO:0004262
cannabis dependence	2	MONDO:0005689	EFO:0007191
secondary progressive multiple sclerosis	2	MONDO:0000450	EFO:0008522
sciatica	2	MONDO:0024333	HP:0011868
dysthymic disorder	1	MONDO:0001442	EFO:0008623
colorectal adenocarcinoma	1	MONDO:0005008	EFO:0000365
injury	0	MONDO:0021178	EFO:0000546
type 1 diabetes mellitus	0	MONDO:0005147	MONDO:0005147
brain cancer	0	MONDO:0001657	MONDO:0021632

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 204.

Phase distribution

Phase	Trials
Not specified	54
PHASE4	48
PHASE3	38
PHASE2	35
PHASE1	11
PHASE1/PHASE2	8
EARLY_PHASE1	6
PHASE2/PHASE3	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05976347	PHASE4	RECRUITING	Identifying and Treating Depression in the Orthopaedic Trauma Population
NCT06046859	PHASE4	RECRUITING	Can Immediate Post-injury Fluoxetine Improve the Recovery Trajectories of Victims in Bodily Trauma?
NCT07110831	PHASE4	NOT_YET_RECRUITING	Disposition Kinetics of Dolutegravir Among People Living With HIV With Major Depression in Nigeria
NCT07478796	PHASE4	RECRUITING	TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children
NCT00000373	PHASE4	COMPLETED	Treatment of Obsessive-Compulsive Disorder
NCT00006204	PHASE4	COMPLETED	Drug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine)
NCT00044616	PHASE4	COMPLETED	Relapse Prevention for Bipolar Type-II Disorder
NCT00061113	PHASE4	COMPLETED	Substance Dependent Teens - Impact of Treating Depression Study 1 - 1
NCT00188942	PHASE4	COMPLETED	A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder
NCT00191399	PHASE4	COMPLETED	Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response
NCT00245635	PHASE4	COMPLETED	Fluoxetine in Pediatric Body Dysmorphic Disorder
NCT00247624	PHASE4	COMPLETED	Improving Sleep and Psychological Functioning in People With Depression and Insomnia
NCT00288574	PHASE4	COMPLETED	Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa
NCT00427128	PHASE4	COMPLETED	Prozac Treatment of Major Depression: Discontinuation Study
NCT00449007	PHASE4	TERMINATED	Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism
NCT00485771	PHASE4	COMPLETED	Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression
NCT00533117	PHASE4	COMPLETED	Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder
NCT00557427	PHASE4	TERMINATED	Hypericum vs Fluoxetine for Mild to Moderate Adolescent Depression
NCT00573547	PHASE4	WITHDRAWN	Open Label Trial of Fluoxetine for the Treatment of Depression in Patients With End Stage Renal Disease
NCT00592852	PHASE4	TERMINATED	Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder
NCT00611975	PHASE4	COMPLETED	Effect of Antidepressants on Sex Hormone Levels and Sexual Functioning
NCT00633685	PHASE4	UNKNOWN	Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure
NCT00666757	PHASE4	COMPLETED	A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression
NCT00678574	PHASE4	COMPLETED	The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder
NCT00806234	PHASE4	COMPLETED	Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
NCT00834834	PHASE4	COMPLETED	Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder
NCT00961961	PHASE4	COMPLETED	Prevention of Relapse & Recurrence of Bipolar Depression
NCT01075529	PHASE4	COMPLETED	Early Prediction of Fluoxetine Response
NCT01185977	PHASE4	COMPLETED	Biomarkers of Antidepressant Treatment in Adolescents With Major Depression (The Adolescents MDD Study)
NCT01204086	PHASE4	UNKNOWN	Pharmacogenomics Studies of Antidepressants
NCT01360190	PHASE4	COMPLETED	Neurophysiologic Monitoring of Antidepressant Treatment
NCT01436643	PHASE4	TERMINATED	Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
NCT01699490	PHASE4	UNKNOWN	Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder
NCT01764867	PHASE4	UNKNOWN	Algorithm Guided Treatment Strategies for Major Depressive Disorder
NCT01824433	PHASE4	COMPLETED	Comparison of Venlafaxine and Fluoxetine in the Treatment of Postmenopausal Women With Major Depression
NCT02022709	PHASE4	COMPLETED	Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients
NCT02238977	PHASE4	TERMINATED	Bupropion for Depression in ESRD Patients on Hemodialysis
NCT02357849	PHASE4	TERMINATED	Fluoxetine vs Aripiprazole Comparative Trial (FACT)
NCT02389712	PHASE4	TERMINATED	16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression
NCT02473250	PHASE4	COMPLETED	Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (4) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of DPWG Guideline for fluoxetine and CYP2D6	DPWG	CYP2D6
Annotation of CPIC Guideline for fluoxetine and CYP2D6	CPIC	CYP2D6
Annotation of CPIC Guideline for desvenlafaxine, duloxetine, fluoxetin	CPIC	HTR2A
Annotation of CPIC Guideline for citalopram, desvenlafaxine, duloxetin	CPIC	SLC6A4

PharmGKB also curates 27 clinical and 197 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

739 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
Desipramine	ChEMBL + PubChem	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, SLC29A4, SLC6A4
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
NITAZOXANIDE	ChEMBL + PubChem	Phase 4 (approved)	ANO1, HTR2A, HTR2B, HTR2C, SLC6A4
Verapamil	ChEMBL + PubChem	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, SLC29A4, SLC6A4
AMIODARONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
AMOXAPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
ASENAPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
AZELASTINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
BENZTROPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
CARIPRAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
CARVEDILOL	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
CINACALCET	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
CLEMASTINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
CLOZAPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
DESLORATADINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
DIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
DOXEPIN	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
EBASTINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
ECONAZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
FLUSPIRILENE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
HALOPERIDOL	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
ILOPERIDONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
IMIPRAMINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
KETANSERIN	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
LOXAPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
MEPAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
METHAPYRILENE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
MIANSERIN	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
MICONAZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
NEFAZODONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
OLANZAPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
ORPHENADRINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
PIMOZIDE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
PIPAMAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
PROMAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
PROMETHAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
PROPAFENONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
PROPRANOLOL	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
RALOXIFENE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
RISPERIDONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
SERTINDOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
SUNITINIB	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
TAMOXIFEN	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
TEGASEROD	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
TERFENADINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
THIORIDAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
ZIPRASIDONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4
ENCLOMIPHENE	ChEMBL	Phase 3	HTR2A, HTR2B, HTR2C, HTR6, SLC6A4